OXYGEN ( DrugBank: Oxygen )

---

20 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2
13	多発性硬化症／視神経脊髄炎	1
19	ライソゾーム病	1
46	悪性関節リウマチ	1
49	全身性エリテマトーデス	1
70	広範脊柱管狭窄症	2
84	サルコイドーシス	1
85	特発性間質性肺炎	12
86	肺動脈性肺高血圧症	6
88	慢性血栓塞栓性肺高血圧症	6
90	網膜色素変性症	2
96	クローン病	2
97	潰瘍性大腸炎	2
168	エーラス・ダンロス症候群	1
193	プラダー・ウィリ症候群	1
226	間質性膀胱炎（ハンナ型）	3
271	強直性脊椎炎	1
294	先天性横隔膜ヘルニア	1
299	嚢胞性線維症	8
330	先天性気管狭窄症／先天性声門下狭窄症	1

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03229174 (ClinicalTrials.gov)	August 23, 2018	21/4/2017	Brain Perfusion & Oxygenation in Parkinson's Disease With NOH	Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo	Parkinson Disease;Neurogenic Orthostatic Hypotension	Drug: Droxidopa;Drug: Placebo	William Ondo, MD	Lundbeck LLC	Recruiting	18 Years	85 Years	All	28	Phase 4	United States
2	NCT03407378 (ClinicalTrials.gov)	June 26, 2018	15/1/2018	A Study to Investigate a New Treatment in Patients With Parkinson's Disease	A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease	Parkinson Disease	Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment	Tools4Patient	NULL	Completed	35 Years	N/A	All	110	Phase 1/Phase 2	United States;Belgium;France

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03983720 (ClinicalTrials.gov)	January 21, 2020	7/6/2019	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Sclerosis, Multiple	Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation	Centre Hospitalier Universitaire de Saint Etienne	NULL	Recruiting	18 Years	70 Years	All	60	Phase 2	France

19. ライソゾーム病

---

臨床試験数 : 854 /  薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02023086 (ClinicalTrials.gov)	August 2014	10/12/2013	Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients	Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Relation With Visual Field Loss in Fabry Patients	Fabry Disease	Procedure: Contrast sensitivity measurement;Procedure: Slit Lamp assessment and intra-ocular pressure measurement;Procedure: Visual field testing;Procedure: Oxygen flow at the optic nerve head measurement;Drug: Tropicamide;Device: OSOME	Université de Montréal	Genzyme, a Sanofi Company	Completed	18 Years	N/A	All	8	N/A	Canada

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02984943 (ClinicalTrials.gov)	January 19, 2017	15/11/2016	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study	RheumatoId Arthritis	Device: Hyperbaric Oxygen	David Grant U.S. Air Force Medical Center	NULL	Completed	18 Years	N/A	All	14	N/A	United States

49. 全身性エリテマトーデス

---

臨床試験数 : 946 /  薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-IOR-17012802	2017-09-26	2017-09-26	Synergy effects and health regulation effect of oxygen-ozone therapy on systemic lupus erythematosus (SLE)	Synergy effects and health regulation effect of oxygen-ozone therapy on systemic lupus erythematosus (SLE)	systemic lupus erythematosus (SLE)	the Controled Group:basic oral therapy;the Treated Group:basic oral therapy + Autologous blood transfusion with oxygen-ozone + acupoint injection with oxygen-ozone on ST 36;	Guangdong Provincial Hospital of Chinese Medicine	NULL	Recruiting	18	65	Both	the Controled Group:30;the Treated Group:30;		China

70. 広範脊柱管狭窄症

---

臨床試験数 : 96 /  薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03088306 (ClinicalTrials.gov)	July 1, 2017	22/2/2017	Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients	Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery	Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration	Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin]	Johns Hopkins University	North American Spine Society	Completed	18 Years	100 Years	All	49	Early Phase 1	United States
2	NCT02625194 (ClinicalTrials.gov)	January 1, 2016	25/11/2015	The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation	The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation	Lumbar Spinal Stenosis	Drug: Oxygen	Yonsei University	NULL	Completed	20 Years	60 Years	All	36	N/A	Korea, Republic of

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02246023 (ClinicalTrials.gov)	January 2015	15/9/2014	Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy	Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.	Lung Cancer;Sarcoidosis;Interstitial Pneumonia	Device: Flexible bronchoscopy in moderate sedation;Device: Oxygen saturation;Device: Blood pressure;Device: Propofol dosage;Device: Recovery time after bronchoscopy	Daniel Franzen	B. Braun Melsungen AG	Completed	18 Years	85 Years	Both	78	Phase 4	Switzerland

85. 特発性間質性肺炎

---

臨床試験数 : 598 /  薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04564664 (ClinicalTrials.gov)	March 1, 2019	14/9/2020	High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis	High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis: a Crossover Clinical Trial	Idiopathic Pulmonary Fibrosis	Drug: Oxygen	Parc de Salut Mar	Hospitales Universitarios Virgen del Rocío	Completed	18 Years	85 Years	All	10	N/A	Spain
2	NCT03688334 (ClinicalTrials.gov)	June 1, 2018	20/9/2018	Acute Effects of Oxygen Supplementation Among IPF Patients	Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia	Idiopathic Pulmonary Fibrosis	Drug: Oxygen 40 %;Drug: Medical air (sham O2)	George Papanicolaou Hospital	NULL	Unknown status	18 Years	80 Years	All	15	N/A	Greece
3	EUCTR2017-001276-27-GB (EUCTR)	21/08/2017	03/05/2017	A study to determine if GBT440 can increase the level of oxygen in the blood of people with Idiopathic Pulmonary Fibrosis (IPF) who need to use supplemental oxygen when resting.	A Phase II open label study to evaluate the effect of GBT440 on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF) who are using supplemental oxygen at rest (ZEPHYR) - ZEPHYR	Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: GBT440 300 mg capsule Product Code: GBT440 Product Name: GBT440 300 mg tablet Product Code: GBT440	Global Blood Therapeutics Inc.	NULL	Not Recruiting			Female: yes Male: yes	32	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United States;United Kingdom
4	NCT03050255 (ClinicalTrials.gov)	November 2016	25/11/2016	Short-term Effects of Supplemental Oxygen in Patients With IPF	Short-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Other: Medical air;Other: Oxygen (2Liter/min);Other: Oxygen (4Liter/min)	Schön Klinik Berchtesgadener Land	Linde AG	Completed	N/A	N/A	All	53	N/A	Germany
5	NCT02989168 (ClinicalTrials.gov)	November 2016	28/11/2016	Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest	A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)	Idiopathic Pulmonary Fibrosis;Hypoxemia	Drug: GBT440	Global Blood Therapeutics	NULL	Terminated	45 Years	85 Years	All	14	Phase 2	United States;United Kingdom
6	NCT02551068 (ClinicalTrials.gov)	December 2015	1/9/2015	High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib	High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study	Idiopathic Pulmonary Fibrosis	Other: 60% Oxygen;Other: Standard of Care	University of British Columbia	Boehringer Ingelheim	Recruiting	19 Years	N/A	All	88	N/A	Canada
7	NCT02267655 (ClinicalTrials.gov)	May 2015	7/10/2014	3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF	An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3)	Pulmonary Hypertension;Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis	Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr;Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;Drug: inhaled nitric oxide 75 mcg/kg IBW/hr	Bellerophon	NULL	Completed	40 Years	80 Years	All	8	Phase 1	Belgium
8	EUCTR2014-003423-21-BE (EUCTR)	29/09/2014	29/08/2014	Evaluation of impact of inhaled nitric oxide on pulmonary vessel blood volume measured by high resolution computed tomography (HRCT) in subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in subjects with WHO Group 3 Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) on Long-Term Oxygen Therapy (LTOT) (Part 2).	An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic pulmonary fibrosis (IPF) on LTOT (Part 2).	Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1;Level: LLT;Classification code 10010952;Term: COPD;Classification code 10009033;Term: Chronic obstructive pulmonary disease;Classification code 10037400;Term: Pulmonary hypertension;Level: HLT;Classification code 10037401;Term: Pulmonary hypertensions;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: INOmax 400ppm mol/mol inhalation gas Product Name: INO INN or Proposed INN: NITRIC OXIDE	Bellerophon Pulse Technologies LLC	NULL	Not Recruiting			Female: yes Male: yes		Phase 1;Phase 2	Belgium
9	NCT02248064 (ClinicalTrials.gov)	July 2014	12/9/2014	Auto-titrating Oxygen in Chronic Respiratory Failure	The Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)	Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis	Device: Auto-titrating oxygen system	Imperial College London	NULL	Completed	18 Years	N/A	Both	26	N/A	United Kingdom
10	NCT01214187 (ClinicalTrials.gov)	July 2011	30/9/2010	Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis	Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: inhaled carbon monoxide;Other: Oxygen	Brigham and Women's Hospital	National Heart, Lung, and Blood Institute (NHLBI);University of California, San Francisco;University of Chicago;University of Illinois at Chicago;University of Michigan;Columbia University;Tulane University;University of Washington	Completed	18 Years	85 Years	All	58	Phase 2	United States
11	JPRN-UMIN000005098	2011/02/01	18/02/2011	A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemia		idiopathic pulmonary fibrosis	ambulatory oxygen ambulatory air	Department of Respiratory Medicine and Allergology, Kinki University School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
12	JPRN-UMIN000025256	2009/01/01	13/12/2016	Benefits of supplemental oxygen on exercise capacity and dyspnea in IPF patients		idiopathic pulmonary fibrosis	oxygen gas air gas	Tosei General Hospital	NULL	Complete: follow-up complete	Not applicable	75years-old	Male and Female	106	Not applicable	Japan

先頭へ

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,181 /  薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04207593 (ClinicalTrials.gov)	April 1, 2019	17/12/2019	The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia	Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH	Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH	Drug: Oxygen	Heidelberg University	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	Germany
2	EUCTR2018-001387-39-DE (EUCTR)	15/03/2019	30/01/2019	The effect of oxygen therapy in patients with pulmonary Hypertension.	A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA	pulmonary arterial hypertension (PAH) and chronic thromboembolicpulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Oxygen, liquid INN or Proposed INN: OXYGEN Other descriptive name: Sauerstoff	Thoraxklinik-Heidelberg gGmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Germany
3	NCT03683082 (ClinicalTrials.gov)	June 5, 2018	20/9/2018	Oxygen Treatment and Pulmonary Arterial Hypertension	Acute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension Patients	Pulmonary Arterial Hypertension	Drug: Oxygen supplementation;Drug: Sham O2 (medical air)	George Papanicolaou Hospital	NULL	Unknown status	18 Years	80 Years	All	10	N/A	Greece
4	NCT02661802 (ClinicalTrials.gov)	January 2012	20/1/2016	Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome	Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome	Eisenmenger Complex;Hypertension, Pulmonary	Other: Oxygen Supplementation	Federal University of São Paulo	NULL	Completed	18 Years	60 Years	Both	30	N/A	NULL
5	NCT00626028 (ClinicalTrials.gov)	September 2004	20/2/2008	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing	Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing	Idiopathic Pulmonary Arterial Hypertension;Cardiomyopathy	Drug: Nitric Oxide for inhalation;Drug: Oxygen;Drug: Nitric Oxide plus Oxygen	Mallinckrodt	NULL	Completed	N/A	18 Years	All	136	Phase 3	United States;France;Netherlands;Spain;United Kingdom
6	NCT00317486 (ClinicalTrials.gov)	September 2003	21/4/2006	Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology	Pulmonary Arterial Hypertension Related to Eisenmenger Physiology	Drug: bosentan	Actelion	NULL	Completed	12 Years	N/A	Both	54	Phase 4	United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom

先頭へ

88. 慢性血栓塞栓性肺高血圧症

---

臨床試験数 : 159 /  薬物数 : 118 - (DrugBank : 23) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 53

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04207593 (ClinicalTrials.gov)	April 1, 2019	17/12/2019	The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia	Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH	Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH	Drug: Oxygen	Heidelberg University	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	Germany
2	EUCTR2018-001387-39-DE (EUCTR)	15/03/2019	30/01/2019	The effect of oxygen therapy in patients with pulmonary Hypertension.	A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA	pulmonary arterial hypertension (PAH) and chronic thromboembolicpulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Oxygen, liquid INN or Proposed INN: OXYGEN Other descriptive name: Sauerstoff	Thoraxklinik-Heidelberg gGmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Germany
3	NCT02558582 (ClinicalTrials.gov)	September 2015	14/9/2015	Effect of Exercise Training in Patients With Pulmonary Hypertension	Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries	Hypertension, Pulmonary	Behavioral: respiratory and exercise therapy;Behavioral: respiratory and exercise therapy with supplemental oxygen	University of Zurich	NULL	Recruiting	18 Years	N/A	All	32	N/A	Switzerland
4	JPRN-UMIN000026882	2015/04/01	10/04/2017	Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.	Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension. - Effect of oxygen administration on PVR and CI in CTEPH.	chronic thromboembolic pulmonary hypertension.	Oxygen administration	Department of Cardiology, Hospital Organization Okayama Medical Center	NULL	Complete: follow-up continuing	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
5	NCT01884012 (ClinicalTrials.gov)	May 2013	13/5/2013	Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension		Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension	Procedure: long term oxygen therapy	University of Zurich	NULL	Completed	16 Years	85 Years	All	30	Phase 3	Switzerland
6	NCT01748474 (ClinicalTrials.gov)	December 2012	4/10/2012	Effect of Short-term Oxygen During CPET in Pulmonary Hypertension	Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension	Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension;Chronic Cardiorespiratory Disease	Procedure: Supplemental oxygen via a mask	University of Zurich	NULL	Completed	20 Years	80 Years	Both	20	Phase 2	Switzerland

先頭へ

90. 網膜色素変性症

---

臨床試験数 : 130 /  薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02465749 (ClinicalTrials.gov)	May 2015	22/5/2015	Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa	Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tid	Sun Yat-sen University	Zhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd.	Not yet recruiting	18 Years	60 Years	Both	404	Phase 0	China
2	NCT00461435 (ClinicalTrials.gov)	January 2004	17/4/2007	Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa	Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa	Retinitis Pigmentosa	Procedure: hyperbaric oxygen therapy	Azienda Policlinico Umberto I	NULL	Completed	20 Years	70 Years	Both		N/A	Italy

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800019958	2018-12-16	2018-12-09	Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease	Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease	Crohn's disease	Case series:Combining infliximab treatmentwith Hyperbaric Oxygen Therapy;	Daping Hospital, Army Medical University (Third Military Medical University)	NULL	Recruiting	18	65	Both	Case series:60;		China
2	NCT01828190 (ClinicalTrials.gov)	March 2013	8/4/2013	The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers	Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers	Crohn's Disease;Perianal Fistulas	Other: Hyperbaric oxygen	Assaf-Harofeh Medical Center	NULL	Recruiting	18 Years	70 Years	Both	50	N/A	Israel

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03494764 (ClinicalTrials.gov)	September 7, 2017	4/4/2018	Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares	Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-Center Randomized Trial	Colitis, Ulcerative	Other: Hyperbaric Oxygen Therapy	Dartmouth-Hitchcock Medical Center	Foundation for Clinical Research in IBD;The Eli and Edythe Broad Foundation;University of California, San Diego;Mayo Clinic;University of Pittsburgh Medical Center;Virginia Mason Memorial Hospital;University of Texas Southwestern Medical Center;University of Maryland, College Park;NYU Langone Health	Completed	18 Years	N/A	All	39	Phase 2	United States
2	NCT02144350 (ClinicalTrials.gov)	August 2013	13/5/2014	Hyperbaric Oxygen for Ulcerative Colitis	Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-center Randomized Double Blind Sham Controlled Trial	Ulcerative Colitis	Procedure: Hyperbaric oxygen;Procedure: Sham Hyperbaric Air	Dartmouth-Hitchcock Medical Center	Mayo Clinic;University of Pittsburgh	Terminated	18 Years	N/A	All	18	Phase 2/Phase 3	United States

168. エーラス・ダンロス症候群

---

臨床試験数 : 8 /  薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 55

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04890431 (ClinicalTrials.gov)	June 2021	6/5/2021	Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome	Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study	Ehlers-Danlos Syndrome	Drug: Oxygen;Drug: Placebo	Hospital St. Joseph, Marseille, France	NULL	Not yet recruiting	18 Years	N/A	All	82	Phase 4	NULL

193. プラダー・ウィリ症候群

---

臨床試験数 : 111 /  薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03031626 (ClinicalTrials.gov)	September 1, 2016	20/1/2017	Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome	Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study	Sleep Apnea, Central;Prader-Willi Syndrome	Biological: Medical Air vs Oxygen	The Hospital for Sick Children	NULL	Recruiting	N/A	2 Years	All	10	Phase 4	Canada

226. 間質性膀胱炎（ハンナ型）

---

臨床試験数 : 143 /  薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03143920 (ClinicalTrials.gov)	November 1, 2017	2/5/2017	Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder	Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility Trial	Chronic Interstitial Cystitis;Painful Bladder Syndrome;Recurrent Urinary Tract Infection	Combination Product: Hyperbaric Oxygen Therapy-	University of California, San Diego	NULL	Recruiting	35 Years	70 Years	Female	40	Early Phase 1	United States
2	NCT03693001 (ClinicalTrials.gov)	June 1, 2016	28/9/2018	HBOT for Patients With IC/FM (Interstitial Cystitis/Fibromyalgia)	Clinical and Morphological Effects of Hyperbaric Oxygen Therapy in Patients With Interstitial Cystitis Associated With Fibromyalgia	Fibromyalgia;Interstitial Cystitis	Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask	University of South Florida	University of Padova	Completed	18 Years	N/A	All	12	N/A	NULL
3	NCT01069263 (ClinicalTrials.gov)	February 2010	10/1/2010	Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis	Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial	Interstitial Cystitis	Other: Hyperbaric Oxygen Therapy;Drug: DMSO	Assaf-Harofeh Medical Center	NULL	Recruiting	18 Years	85 Years	Both	60	N/A	Israel

271. 強直性脊椎炎

---

臨床試験数 : 563 /  薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100042477	2021-02-01	2021-01-22	High-flow nasal cannula oxygen during endotracheal intubation in patients with ankylosing spondylitis: a prospective, single-arm study	High-flow nasal cannula oxygen during endotracheal intubation in patients with ankylosing spondylitis : a prospective, single-arm study	ankylosing spondylitis	Group HFNC:Nasal high-flow oxygen inhalation before tracheal intubation;	Shenzhen Second People's Hospital	NULL	Pending	18	50	Both	Group HFNC:30;		China

294. 先天性横隔膜ヘルニア

---

臨床試験数 : 15 /  薬物数 : 36 - (DrugBank : 6) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03787160 (ClinicalTrials.gov)	March 22, 2018	10/7/2018	Microbiome and Volatile Organic Compounds in Patients With CDH	Determining the Effect of Probiotics on Microbiome and Volatile Organic Compounds in Patients After Surgical Repair of Congenital Diaphragmatic Hernia	Congenital Diaphragmatic Hernia	Diagnostic Test: initial VOC;Diagnostic Test: initial fecal microbiome;Diagnostic Test: initial pulmonary microbiome;Diagnostic Test: Maximum oxygen uptake;Diagnostic Test: Functional residual capacity;Dietary Supplement: Probiotic treatment;Diagnostic Test: VOC probiotic;Diagnostic Test: Fecal microbiome probiotic;Diagnostic Test: Pulmonary microbiome probiotic	Medical University of Graz	University of Rostock	Completed	6 Years	16 Years	All	18	N/A	Austria

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03965832 (ClinicalTrials.gov)	May 24, 2019	24/5/2019	HFNT During Exercise in CF	A Pilot Study to Evaluate the Feasibility of Using High-flow Nasal Therapy During Exercise in Patients With Cystic Fibrosis and Severe Lung Disease	Cystic Fibrosis	Device: HFNT during exercise;Device: Standard oxygen therapy/RA	The Leeds Teaching Hospitals NHS Trust	NULL	Recruiting	18 Years	N/A	All	20	N/A	United Kingdom
2	NCT03902236 (ClinicalTrials.gov)	March 1, 2019	1/4/2019	Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis	Evaluation of Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis	Cystic Fibrosis;Bronchiectasis	Other: Reaction Time and Postural Control;Other: Muscle oxygenation;Other: Exercise capacity;Other: Balance	Hacettepe University	NULL	Recruiting	6 Years	18 Years	All	60		Turkey
3	NCT02684552 (ClinicalTrials.gov)	February 2016	12/2/2016	Non Invasive Ventilation During Physical Training in Cystic Fibrosis	Physiotherapist in Charge of the Study	Cystic Fibrosis	Device: Non invasive ventilation;Device: Oxygen	Karolinska University Hospital	NULL	Completed	18 Years	90 Years	Both	8	N/A	Sweden
4	NCT02262871 (ClinicalTrials.gov)	December 2014	7/10/2014	HFN Versus NIV in Cystic Fibrosis. The HIFEN Study	Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study	Cystic Fibrosis	Device: High flow nasal oxygen cannula;Device: Noninvasive ventilation	St. Michael's Hospital, Toronto	NULL	Completed	18 Years	N/A	All	15	N/A	Canada
5	NCT01586728 (ClinicalTrials.gov)	October 2012	18/1/2012	Oxygen Therapy in Cystic Fibrosis	Indication and Benefits of Nocturnal Oxygen Therapy in Cystic Fibrosis	Cystic Fibrosis	Other: Air - oxygen;Other: Oxygen - Air	Assistance Publique - Hôpitaux de Paris	Vaincre la Mucoviscidose	Terminated	6 Years	N/A	Both	8	N/A	France
6	NCT01731015 (ClinicalTrials.gov)	January 2012	16/11/2012	Imaging Lung Function Using Oxygen Enhanced MRI	A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent	COPD;Asthma;Cystic Fibrosis;Emphysema;Small Airways Disease	Drug: Medical Grade Oxygen	Hal C Charles	NULL	Completed	18 Years	90 Years	Both	15	Phase 1	United States
7	NCT01710449 (ClinicalTrials.gov)	September 2009	17/10/2012	Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen	Evaluation of Regional Ventilation in Normal Subjects and Subjects With Airway and Lung Disorders (COPD, Asthma, Emphysema, Small Airway Disease and Cystic Fibrosis) Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen.	COPD;Asthma;Cystic Fibrosis;Emphysema;Small Airways Diseases	Drug: perfluorinated gas/oxygen mixture	Hal C Charles	NULL	Completed	18 Years	N/A	Both	44	Phase 1	United States
8	NCT00157183 (ClinicalTrials.gov)	March 2003	9/9/2005	Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation	Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation	Cystic Fibrosis	Device: Nocturnal oxygen , nocturnal bi-level positive pressure ventilation	Bayside Health	National Health and Medical Research Council, Australia;Monash University;Cystic Fibrosis Australia	Completed	18 Years	75 Years	Both	59	Phase 1/Phase 2	Australia

先頭へ

330. 先天性気管狭窄症／先天性声門下狭窄症

---

臨床試験数 : 1 /  薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00357	01/07/2018	19/06/2018	Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children	Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children	Respiratory failure due to airway obstructive lesion such as acute bronchiolitis, congenital tracheal stenosis, bronchial asthma attack	Intervention type:DRUG. Intervention1:Helium / oxygen mixed gas inhalation therapy, Dose form:INSUFFLATION, Route of administration:INHALATIONAL, intended dose regimen:Helium / oxygen mixed gas .	Tokyo Metropolitan Children's Medical Center	National Center for Child Health and Development	Recruiting	No Limit	<20 YEARS	BOTH	15	Phase 2	Japan

先頭へ